I think XXII is nearing its end with Sabby- we will learn more on that soon via filings
They have lots of catalyst- British American milestone payments- clearing out Sabby of course- Pfizer- more licensing agreements- production of their modified risk cig's etc. etc.
just the partner they landed alone should command them a better valuation imo- but they flushed several out recently with Sabby's selling to go with a few small insider sells which didn't help confidence either.
When in doubt it sometimes pays to turn to technical analysis. Now while I have no idea where the price will be in the future, the chart shows the trend that brought the stock from .15 to 1.75 is still intact.